Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
American Journal of Psychiatry · 2025
DOI: 10.1176/appi.ajp.20230902 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Psychiatry, 2025. Verfasst von Roger S McIntyre und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry (McIntyre, Mansur, Rosenblat) and Department of Pharmacology and Toxicology (McIntyre, Mansur, Rosenblat), University of Tor…. Hauptthemen laut MEDLINE: Hallucinogens, Mental Disorders. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 161 Literaturangaben.
Abstract (Originalsprache)
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary evidence also supports efficacy in other psychiatric disorders (e.g., tobacco and alcohol use disorders). Notwithstanding the interest and promise of psychedelics, concerns have arisen with respect to the interpretability and translatability of study results. For example, aspects related to short- and long-term safety, abuse liability, and the essentiality of the psychedelic "trip" and psychological support are, inter alia, insufficiently characterized with psychedelic agents. The overarching aims in this overview are 1) to review methodological aspects that affect inferences and interpretation of extant psychedelic studies in psychiatric disorders, and 2) to provide guidance for future research and development of psychedelic treatment in psychiatry, critical to study interpretation and clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry (McIntyre, Mansur, Rosenblat) and Department of Pharmacology and Toxicology (McIntyre, Mansur, Rosenblat), University of Toronto, Toronto; Brain and Cognition Discovery Foundation, Toronto (Kwan…
Zitieren
APA
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T., Stahl, S. M., & Rosenblat, J. D. (2025). Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230902
Vancouver
McIntyre RS, Kwan ATH, Mansur RB, Oliveira-Maia AJ, Teopiz KM, Maletic V, et al. Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. American Journal of Psychiatry. 2025. doi:10.1176/appi.ajp.20230902
BibTeX
@article{McIntyre2025,
author = {McIntyre, Roger S and Kwan, Angela T H and Mansur, Rodrigo B and Oliveira-Maia, Albino J and Teopiz, Kayla M and Maletic, Vladimir and Suppes, Trisha and Stahl, Stephen M and Rosenblat, Joshua D},
title = {Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research},
journal = {American Journal of Psychiatry},
year = {2025},
doi = {10.1176/appi.ajp.20230902}
}
EUVIMED